A recent study by the Department of Nephrology/Nephropathy Research Institute at West China Hospital of Sichuan University has revealed that the metabolic enzyme ACSS2 mediates histone butyrylation modification, which can alleviate renal fibrosis, providing a potential drug target for chronic kidney disease. The findings were published in Nature Communications.
The research explored the role of histone butyrylation modification in the process of renal fibrosis and its association with disease progression, expanding the understanding of the pathogenesis of chronic kidney disease (CKD) and providing potential drug targets for the prevention and treatment of this disease, with significant clinical implications.
The study found that targeted intervention of the metabolic enzyme ACSS2 can precisely regulate histone butyrylation modification, thereby reducing its mediated IL-1β transcriptional expression, effectively alleviating macrophage activation and renal tubular cell senescence, and mitigating renal fibrosis. This discovery offers a new perspective and therapeutic strategy for delaying renal aging and fibrosis.
Link to the paper
